Genomma Lab Internacional Sab De Cv Reports Earnings Results for the Third Quarter Ended September 30, 2019
October 23, 2019 at 04:59 am EDT
Share
Genomma Lab Internacional SAB de CV announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced sales was MXN 3,077.305 million compared to MXN 2,734.826 million a year ago. Operating income was MXN 581.448 million compared to MXN 524.124 million a year ago. Net income was MXN 233.387 million compared to MXN 223.722 million a year ago. For the nine months, sales was MXN 9,492.619 million compared to MXN 8,670.353 million a year ago. Operating income was MXN 1,811.846 million compared to MXN 1,749.106 million a year ago. Net income was MXN 728.823 million compared to MXN 903.667 million a year ago.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
